LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani
LB Pharmaceuticals (NASDAQ:LBRX) has strengthened its Board of Directors with two strategic appointments following its IPO on September 10, 2025. The company has added William Kane, current President and CEO of Uniquity Bio with extensive commercialization experience, and Rekha Hemrajani, who brings significant financial and operational expertise.
These appointments come at a crucial time as LB Pharmaceuticals prepares to advance its lead product candidate, LB-102, into Phase 3 trials for acute schizophrenia and Phase 2 trials for bipolar depression in early 2026. LB-102 is positioned to potentially become the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States.
LB Pharmaceuticals (NASDAQ:LBRX) ha rafforzato il proprio Consiglio di Amministrazione con due nomine strategiche dopo l’IPO del 10 settembre 2025. L'azienda ha aggiunto William Kane, attuale Presidente e CEO di Uniquity Bio, con una vasta esperienza nella commercializzazione, e Rekha Hemrajani, che porta una significativa expertise finanziaria e operativa.
Queste nomine arrivano in un momento cruciale mentre LB Pharmaceuticals si prepara ad avanzare il suo candidato principale, LB-102, in studi di fase 3 per la schizofrenia acuta e studi di fase 2 per la depressione bipolare all’inizio del 2026. LB-102 è posizionato per diventare potenzialmente il primo antipsicotico a base di benzamidi approvato per disturbi neuropsichiatrici negli Stati Uniti.
LB Pharmaceuticals (NASDAQ:LBRX) ha fortalecido su Junta Directiva con dos nombramientos estratégicos tras su OPI el 10 de septiembre de 2025. La compañía ha incorporado a William Kane, actual Presidente y Director Ejecutivo de Uniquity Bio, con amplia experiencia en comercialización, y a Rekha Hemrajani, quien aporta una significativa experiencia financiera y operativa.
Estos nombramientos llegan en un momento crucial mientras LB Pharmaceuticals se prepara para avanzar su candidato principal de producto, LB-102, a ensayos de fase 3 para esquizofrenia aguda y ensayos de fase 2 para depresión bipolar a principios de 2026. LB-102 está posicionado para convertirse potencialmente en el primer fármaco antipsicótico a base de benzamida aprobado para trastornos neuropsiquiátricos en Estados Unidos.
LB Pharmaceuticals (NASDAQ:LBRX)가 IPO 2025년 9월 10일 이후 이사회에 두 명의 전략적 임명을 통해 강화되었습니다. 기업은 William Kane를 영입했으며, 그는 현재 Uniquity Bio의 사장 겸 최고경영자이며 광범위한 상용화 경험을 보유하고 있습니다. 또한 Rekha Hemrajani를 영입하여 재무 및 운영 측면에서 큰 전문 지식을 제공합니다.
이 임명은 LB Pharmaceuticals가 주력 후보물질인 LB-102를 2026년 초에 급성 조현병에 대한 3상 임상 및 양극성 우울증에 대한 2상 임상으로 진입하기 준비를 하는 결정적 시점에 이뤄졌습니다. LB-102는 미국에서 신경정신과 질환에 대해 benzamide 계열의 최초의 항정신병 약물이 될Potential 가능성을 가진 것으로 평가됩니다.
LB Pharmaceuticals (NASDAQ:LBRX) a renforcé son conseil d’administration avec deux nominations stratégiques après son introduction en bourse le 10 septembre 2025. La société a recruté William Kane, actuellement président et PDG d’Uniquity Bio, fort d’une vaste expérience en commercialisation, et Rekha Hemrajani, qui apporte une expertise financière et opérationnelle significative.
Ces nominations interviennent à un moment crucial alors que LB Pharmaceuticals se prépare à faire progresser son candidat principal, LB-102, vers des essais de phase 3 pour la schizophrénie aiguë et des essais de phase 2 pour la dépression bipolaire au début de 2026. LB-102 est bien positionné pour potentiellement devenir le premier médicament antipsychotique à base de benzamide approuvé pour les troubles neuropsychiatriques aux États‑Unis.
LB Pharmaceuticals (NASDAQ:LBRX) hat seinen Vorstand mit zwei strategischen Neubesetzungen nach dem IPO am 10. September 2025 gestärkt. Das Unternehmen hat William Kane, den aktuellen Präsidenten und CEO von Uniquity Bio, mit umfangreicher Vermarktungserfahrung, und Rekha Hemrajani, die über erhebliche finanzielle und operative Expertise verfügt, hinzugeholt.
Diese Neubesetzungen erfolgen zu einem entscheidenden Zeitpunkt, da LB Pharmaceuticals darauf vorbereitet ist, seinen Leitkandidaten LB-102 in Phase-3-Studien für akute Schizophrenie und Phase-2-Studien für bipolare Depression Anfang 2026 voranzutreiben. LB-102 hat das Potenzial, möglicherweise das erste benzamidsche Antipsychotikum zu werden, das in den USA für neuropsychiatrische Erkrankungen zugelassen wird.
LB Pharmaceuticals (NASDAQ:LBRX) عزّزت مجلس إدارتها بترشيحين استراتيجيين بعد طرحها للاكتتاب العام في 10 سبتمبر 2025. أضيف إلى الشركة ويليام كين، الرئيس التنفيذي الحالي لشركة Uniquity Bio، الذي يمتلك خبرة واسعة في التسويق، وريخا هيمراجاني، التي تجلب خبرة مالية وتشغيلية كبيرة.
يأتي هذه الترقيات في وقت حاسم بينما تستعد LB Pharmaceuticals لتقدم مرشحها الرئيسي LB-102 إلى التجارب السريرية من المرحلة 3 للاصابة بالشيزوفرينيا الحاد و التجارب من المرحلة 2 للاكتئاب الثنائي القطب في أوائل 2026. من المرجح أن يصبح LB-102 أول دواء مضاد للذهان قائم على بنزاميد معتمد لعلاج الاضطرابات العصبية النفسية في الولايات المتحدة.
LB Pharmaceuticals (NASDAQ:LBRX) 在其于2025年9月10日进行首次公开招股后，通过两位战略任命加强了董事会。公司任命了 William Kane，现任 Uniquity Bio 的总裁兼首席执行官，拥有丰富的商业化经验，以及 Rekha Hemrajani，她带来了显著的财务与运营专长。
在 LB Pharmaceuticals 准备将其主导产品候选药物 LB-102 推进至 2026 年初的急性精神分裂症三期临床以及 双相抑郁症二期临床 时，这些任命时机尤为关键。LB-102 有望成为在美国获批的第一种苯甲酰胺类精神科药物，用于神经精神疾病治疗。
- Strategic board appointments bring expertise in commercialization, finance, and corporate governance
- Lead product LB-102 advancing to Phase 3 trials for schizophrenia and Phase 2 for bipolar depression
- Potential to be first benzamide antipsychotic approved for neuropsychiatric disorders in US
- Recent successful IPO completion on September 10, 2025
- None.
NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced the appointments of William Kane and Rekha Hemrajani to its Board of Directors effective as of the pricing of its initial public offering on September 10, 2025. The Company believes Mr. Kane and Ms. Hemrajani add valuable expertise in finance, business development, product commercialization, and corporate strategy to its Board of Directors as the Company advances its lead product candidate, LB-102, into a Phase 3 clinical trial for acute schizophrenia and a Phase 2 clinical trial for bipolar depression. LB Pharmaceuticals is building a pipeline that leverages the broad therapeutic potential of LB-102, which the Company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States.
“Ms. Hemrajani and Mr. Kane have complementary strengths that will accelerate our strategic growth as we approach the initiation of two important clinical trials early next year,” said Heather Turner, Chief Executive Officer of LB Pharmaceuticals. “Ms. Hemrajani’s experience in financial operations and corporate governance and Mr. Kane’s proven track record of commercializing new therapies make them outstanding additions to our Board of Directors. Their guidance will be invaluable as we work to fulfill our mission of bringing safer, more effective neuropsychiatric treatments to patients.”
Mr. Kane brings over three decades of biopharmaceutical leadership to the Board. He is currently President and CEO of Uniquity Bio. He was previously President and CCO at Anthos Therapeutics (through its acquisition by Novartis), CCO at Karuna Therapeutics, where he led the commercialization strategy for Cobenfy, and held senior roles at BioXcel Therapeutics and Allergan, where he helped launch multiple leading branded therapeutics including Namzaric, Vraylar, and Ubrelvy, and at Pfizer, where he was instrumental in the success of multiple blockbuster products, including Zoloft, Zyrtec and Celebrex. He holds an MBA from The Wharton School and a B.A. in Government from Connecticut College.
Mr. Kane commented, “LB Pharmaceuticals has potential to make a significant impact in neuropsychiatric care. LB‑102 offers a compelling balance of clinical activity, tolerability, and simplicity of dosing—qualities that matter deeply to prescribers and patients alike – and I look forward to supporting the Company’s efforts to deliver on this promising potential.”
Ms. Hemrajani currently serves on the boards of directors of ALX Oncology, BioAge Labs, and MaxCyte. Her previous roles include CEO of Aravive, COO and CFO of Arcus Biosciences, COO of RAPT Therapeutics, and CFO of Sagimet Biosciences. She also formerly led Licensing and M&A at Onyx Pharmaceuticals (acquired by Amgen), and Business Development at Exelixis. She holds a B.S. in Economics and Computer Science from the University of Michigan and an MBA from Kellogg School of Management at Northwestern University.
“I am excited to partner with LB Pharmaceuticals at this critical phase as they transition toward late-stage Phase 3 development. The data from the Phase 2 clinical trial of LB-102 provide a strong foundation for further development, and I look forward to helping guide the Company’s path toward its ultimate goal of delivering meaningful impact for patients and physicians alike.”
About LB Pharmaceuticals
LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a potentially attractive alternative to branded and generic therapeutics for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.
About LB-102
LB-102 is a Phase 3-ready oral, small molecule and a methylated derivative of amisulpride. In early 2025, LB Pharmaceuticals announced positive data from a four-week placebo-controlled, double-blinded, Phase 2 trial in patients with acute schizophrenia. The Phase 2 trial demonstrated statistically significant benefit versus placebo at all doses studied, a potentially class leading safety profile among D2 antagonists and partial agonists, and positive effects on negative symptoms and cognition. LB-102 is advancing into a Phase 3 clinical trial for acute schizophrenia and a Phase 2 clinical trial for bipolar depression. Additional expansion opportunities for LB-102 could include major depressive disorder (MDD), predominantly negative symptoms of schizophrenia, Alzheimer’s disease psychosis and agitation, as well as bipolar mania and cognitive impairment associated with schizophrenia.
Cautionary Note Regarding Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” or similar expressions are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning the expected clinical development and regulatory pathway and therapeutic benefits of LB-102, the Company’s ability to commercialize LB-102, if approved; and continuing advancement of LB-102 and the Company’s portfolio. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: the Company’s limited operating history and historical losses; the Company’s ability to raise additional funding to complete the development and any commercialization of LB-102; the Company’s dependence on the success of its lead product candidate, LB-102; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidate; the early stages of clinical development of the Company’s lead product candidate, LB-102; any undesirable side effects or other properties of the Company’s product candidate; that the Company may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; the Company’s ability to obtain, maintain and protect its intellectual property; and the Company’s dependence on third parties in connection with manufacturing, clinical trials and preclinical studies.
These and other risks are described more fully in the Company’s filings with the Securities and Exchange Commission (the “SEC”) and its other documents to be subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Contacts
Media:
Michael Tattory
LifeSci Communications
Mtattory@lifescicomms.com
Investor Relations:
ir@lbpharma.us
FAQ
Who are the new board members appointed to LB Pharmaceuticals (LBRX)?
What is the current development status of LB Pharmaceuticals' (LBRX) lead drug candidate?
What is significant about LB-102's potential in the US market?
When did LB Pharmaceuticals (LBRX) complete its IPO?
What experience does William Kane bring to LB Pharmaceuticals' board?
